About
Adocia is an innovative biotech company specialized in the discovery and development of therapeutic solutions for metabolic diseases.
Adocia, a French clinical-stage biotech company
The core activities of the company are to innovate, to discover and to develop new therapeutic solutions to improve the lives of people suffering from chronic metabolic diseases, such as diabetes and obesity. Adocia innovative products share a common goal: to improve treatments, bringing new medical benefits to patients and covering unmet medical needs. Relying on disruptive technology platforms, Adocia solutions range from innovative formulations of already-approved peptides and proteins to cell therapy.
Since its creation, Adocia has built a unique expertise in diabetes and obesity, the two diseases being closely interlinked. Innovative formulations of insulins, ad other metabolic hormones – hormones playing a pivotal role in diabetes and obesity – are the focus of Adocia. Over the years, Adocia has consolidated a rich specialty product portfolio which is one of the broadest and most differentiated for the treatment of type 1, type 2 diabetes and obesity.
A diversified speciality products pipeline
Adocia pipeline relies on 4 proprietary technology platforms, BioChaperone®, AdoShell®, AdOral® and AdoXLong, with proprietary specialty products in clinical trials ranging from Phase 1 to Phase 3.
Our approach
Adocia business model is to license-out to pharmaceutical companies its proprietary specialty products after proof-of-concept or to partner directly on technology platforms.
